Rongchang Pharma 
Welcome,         Profile    Billing    Logout  
 0 Products   0 Diseases   0 Products   0 Trials   1 News 


«12345678910111213...1314»
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open:  A Study of Telitacicept in Lupus Nephritis (clinicaltrials.gov) -  Oct 12, 2023   
    P2,  N=120, Recruiting, 
    Not yet recruiting --> Recruiting
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion date, Trial primary completion date:  RC18 in Patients With Relapsing Remitting Multiple Sclerosis?a Phase II Trial (clinicaltrials.gov) -  Oct 11, 2023   
    P2,  N=18, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Nov 2022 --> Dec 2025 | Trial primary completion date: Apr 2022 --> Oct 2025
  • ||||||||||  RC28-E / Rongchang Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  Evaluation of RC28-E Injection in Diabetic Retinopathy (clinicaltrials.gov) -  Oct 11, 2023   
    P2,  N=120, Active, not recruiting, 
    Trial completion date: Nov 2022 --> Dec 2025 | Trial primary completion date: Apr 2022 --> Oct 2025 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> May 2024
  • ||||||||||  Aidixi (disitamab vedotin) / Rongchang Pharma, Seagen
    First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_1081;    
    Methods We continuously enrolled patients with ERBB2-altered NSCLC who underwent monotherapy or combination therapy with Disitamab Vedotin (RC48) between August 2021 and March 2023...Conclusions For HER2-altered NSCLC patients, RC48 combined therapies are applicable treatment options, particularly with platinum agents. RC48 combined therapies also offers a new treatment approach for patients with HER2 amplification.
  • ||||||||||  Fruzaqla (fruquintinib) / Takeda, Aidixi (disitamab vedotin) / Pfizer
    Enrollment closed, Metastases:  HCCSC-C03: Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression (clinicaltrials.gov) -  Sep 28, 2023   
    P4,  N=12, Active, not recruiting, 
    Ultimately the regimen achieved the accurate integration of RT, immunotherapy and targeted therapy. Not yet recruiting --> Active, not recruiting
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Review, Journal:  Role of telitacicept in the treatment of IgA nephropathy. (Pubmed Central) -  Sep 26, 2023   
    As a dual-target biological agent, telitacicept can inhibit both BLyS and APRIL cytokines, improve the function of renal immune complexes, and reduce haematuria and proteinuria, which play important roles in IgAN pathogenesis and long-term prognosis. This article reviews the role of telitacicept in IgA nephropathy and discusses its potential for use in the treatment of IgAN and other autoimmune diseases where pathogenesis is driven by B cells.
  • ||||||||||  Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma
    WITHDRAWN (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4319;    
    Telitacicept showed better efficacy and safety than belimumab for patients with active SLE in multiple clinical centers. Further investigations in larger cohorts and head-to-head clinical trials are required to verify these findings.
  • ||||||||||  RC28-E / Rongchang Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Evaluation of RC28-E Injection in Diabetic Macular Edema (clinicaltrials.gov) -  Aug 31, 2023   
    P2,  N=156, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment closed, Enrollment change, Trial primary completion date:  A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy (clinicaltrials.gov) -  Aug 30, 2023   
    P2,  N=15, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023 Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: Jul 2023 --> Feb 2024
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Aidixi (disitamab vedotin) / Pfizer
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) -  Aug 25, 2023   
    P1,  N=50, Recruiting, 
    Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: Jul 2023 --> Feb 2024 Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024
  • ||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Aidixi (disitamab vedotin) / Rongchang Pharma, Seagen, Padcev (enfortumab vedotin-ejfv) / Seagen, Astellas
    Journal, Combination therapy:  Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium. (Pubmed Central) -  Aug 2, 2023   
    Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.
  • ||||||||||  Journal:  Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma. (Pubmed Central) -  Jul 10, 2023   
    To this end, current and future preclinical and translational evaluation of novel treatment strategies should consider these novel compounds in addition to current standard options as well. In this context, the following article will provide an overview of this new class of agents, starting with general information on molecular structure and mode of action, clinical use of ADCs in urothelial carcinoma, and ending with considerations for designing preclinical and translational experiments implementing ADCs.
  • ||||||||||  Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
    Trial initiation date, Metastases:  Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) (clinicaltrials.gov) -  Jul 7, 2023   
    P3,  N=288, Recruiting, 
    In this context, the following article will provide an overview of this new class of agents, starting with general information on molecular structure and mode of action, clinical use of ADCs in urothelial carcinoma, and ending with considerations for designing preclinical and translational experiments implementing ADCs. Initiation date: Mar 2023 --> Jul 2023
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Clinical, P2 data, Journal:  Efficacy and safety of telitacicept in primary Sj (Pubmed Central) -  Jul 3, 2023   
    P2
    Initiation date: Mar 2023 --> Jul 2023 Telitacicept showed clinical benefits and well tolerance and safety in the treatment of pSS.